Large multi-center Phase 3 human clinical trials testing efficacy, absolute risk reduction, and adverse-event rates against placebo or active gold-standard comparators. Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Once-weekly treatment with tirzepatide demonstrated significant reductions in body weight and prespecified cardiometabolic measures compared with placebo in Japanese adults with obesity or overweight.
The mechanism of this iloperidone-induced increase in serum urate levels is likely due to decrease in clearance of urate through interaction with the SLC2A9 urate transporter protein.
The GRANT score was prospectively validated in the PROSPER study, demonstrating prognostic value for both RFS and OS, especially in nonclear RCC, further supporting its use in clinical practice.
This tetanus toxoid-conjugated PCV13 met prespecified criteria for lot-to-lot manufacturing consistency and showed favorable immunogenicity and safety profiles in children aged 2-5 years, supporting its licensed use in this...
Somapacitan provides similar efficacy, safety, and tolerability as daily GH in short children born SGA after 52 weeks of treatment.
Once-weekly somapacitan was confirmed as noninferior and demonstrated superiority to daily GH in HV after 52 weeks of treatment in treatment-naïve children living with Noonan syndrome.
Of 102 patients, 82 (80%) received prior STCs and 59 (58%) had prior IRIC to STCs.
At baseline, 34.7% (234/674) and 35.7% (124/347) of upadacitinib 45 mg and placebo-treated patients were taking corticosteroids, respectively.
MADRS total score (mean change, -8.9, nominal P < 0.0001), CGI-BP-S total score (-2.3, nominal P < 0.0001), and CGI-BP-S depression subscore (-1.3, nominal P < 0.0001) improved over time, from baseline to Day 175.
CONCLUSION: Prophylactic administration of 0.5 µg/kg dexmedetomidine reduced early postoperative sleep disturbances associated with propofol, primarily by preserving REM sleep and mitigating TST and WASO fluctuations.
Accordingly, treatment-naïve patients had a significantly higher gain of BCVA with + 4.6 letters compared to + 1.2 letters (p < 0.01).
These findings reinforce the long-term clinical benefit of edaravone and demonstrate that edaravone may offer benefits across a spectrum of ALS disease trajectories, beyond those defined in the original study criteria.
These findings suggest that LD is not a safe alternative to ND in HSCT patients and patients with AL because of increased infection risk without nutritional or other benefit.
The combination of HESr and alfuzosin was significantly more effective than alfuzosin single-drug treatment in relieving LUTS, with greater benefits from Month 3 onward.
MIS for ICH significantly reduces MLS.
Most REBOOT participants witnessed a recent opioid overdose preceding enrollment.
The results support the HYPO-RT-PC findings by showing similar morbidity between ultra-hypofractionated and standard radiotherapy.
Mirikizumab-treated participants achieved significantly higher rates of BU CMI and full symptom relief at weeks 12 and 52, which was associated with better short- and longer-term clinical outcomes.
Both high- and low-FVC subgroups demonstrated reduced ALS functional rating scale-revised decline at 48 weeks when treated continuously with edaravone.
The superiority of MND-21 3600 mg/d over the placebo was observed, and MND-21 was safe and well tolerated.
Epilepsy-DOOR showed similar effect sizes but slightly reduced power when compared with responder rate.
Over 3 years, donanemab-treated participants with early symptomatic AD demonstrated increasing clinical benefits and a consistent safety profile, with limited-duration dosing.
Lastly, 60% of patients with ≥1-year RBC-TI had ≥50% reduction in telomerase activity/human telomerase reverse transcriptase RNA.
Early findings suggest letrozole is well tolerated and may represent a viable therapeutic option for hormone receptor-positive LGSCO.
Simulations projected the difference in CDR-SB between lecanemab and placebo treated subjects continued increasing over 4 years.
A GTDS-based triple antiemetic regimen can effectively control CINV associated with HEC or MEC.
All three scores demonstrated moderate discriminatory ability while PREDICT v3 and RSClin had better calibration.
Side effects were similar across subgroups.
The responder definitions were at least a 3-point improvement for PROMIS-PF, a 10% improvement for active ROM, and a 2-point improvement for the Worst Stiffness NRS.
After ∼4 years, DOR-based regimens were not associated with changes in ASCVD risk scores in PLWH.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
